Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)
Table 1
Baseline characteristics in each group.
Parameters
Telmisartan
Losartan
P-value
(male/female)
12 (6/6)
7 (3/4)
Age (years)
0.612
Duration of diabetes (years)
0.523
Height (cm)
0.673
Body mass index (kg/m2)
0.735
Waist circumference (cm)
0.899
Hip circumference (cm)
0.257
Systolic blood pressure (mmHg)
0.526
Diastolic blood pressure (mmHg)
0.611
Pulse (beats/min)
0.205
Biochemical markers
Fasting plasma glucose (mg/dL)
0.571
Hemoglobin A1c (%)
0.444
Glycoalbumin (%)
0.447
Immunoreactive insulin (μU/mL)
0.955
Total cholesterol (mg/dL)
0.447
High-density lipoprotein cholesterol (mg/dL)
0.290
Triglyceride (mg/dL)
0.866
Free fatty acids (mEq/L)
0.001
Aspartate aminotransferase (IU/L)
0.372
Alanine aminotransferase (IU/L)
0.583
γ Glutamyl transpeptidase (IU/L)
0.612
Alkaline phosphatase (IU/L)
0.800
Lactate dehydrogenase (IU/L)
0.353
Blood urea nitrogen (mg/dL)
0.704
Creatinine (mg/dL)
0.283
Uric acid (mg/dL)
0.582
Na (mEq/L)
0.447
K (mEq/L)
0.966
u-Microalbumin (μg/mL)
0.375
Ferritin (ng/mL)
0.767
Creatine phosphokinase (IU/L)
0.899
HOMA-IR
0.865
HOMA-β
0.865
Complete blood count
White blood cells (×103/μL)
0.052
Hemoglobin (g/dL)
0.865
Platelets (×103/μL)
0.163
Inflammatory markers
Hyaluronic acid (ng/mL)
0.446
7S domain of type 4 collagen (ng/mL)
0.445
High-sensitivity CRP (mg/dL)
0.964
Procollagen-3-peptide (U/mL)
0.175
Zn (μg/dL)
0.612
Total adiponectin (μg/mL)
0.400
Interleukin-6 (pg/mL)
0.309
Bile acids (BA)
Total BA (μmol/L)
0.331
Primary BA (μmol/L)
0.135
Secondary BA (μmol/L)
0.966
CT scan
Visceral fat (cm2)
0.673
Subcutaneous fat (cm2)
0.877
V/S ratio
0.612
CT-L1 (HU)
0.025
CT-L2 (HU)
0.063
CT-Spleen (HU)
0.866
L/S ratio
0.035
Baseline treatment for hypertension [ (%)]
0.973
Naive
5 (41.7)
3 (42.9)
Other ARB or ACE inhibitor
3 (25.0)
2 (28.6)
Calcium channel blocker
4 (33.3)
2 (28.6)
Baseline treatment for diabetes mellitus [ (%)]
0.123
Diet only
12 (100.0)
5 (71.4)
Sulphonylurea+α-glucosidase inhibitor
0 (0.0)
2 (28.6)
Baseline treatment for lipid abnormality [ (%)]
0.603
Diet only
10 (83.3)
5 (71.4)
HMG-CoA reductase inhibitor (statin)
2 (16.7)
2 (28.6)
Data are mean ± SD. Parameters were compared between groups (telmisartan versus losartan) by Mann-Whitney test or chi-squared test.
